Immunotherapy

Huland, Edith; Heinzer, Hans; Huland, Hartwig

doi:10.1007/978-1-84628-763-3_46

Cited by 3 publications

(4 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Eine Erhöhung des Nierenbeckendruckes führt zu einer Abnahme des effektiven Filtrationsdruckes und damit zu einem vollständigen Sistieren der Ausscheidung. Allerdings muß ein Sistieren der Ausscheidung nicht zwangsläufig zu einer Abnahme der Nierendurchblutung führen, die soweit geht, daß es zu ei- ner ischämischen Schädigung des Nierenparenchyms kommt (13,14,15). Anhand des normalen und veränderten Verhaltens der verschieden großen Proteine können wir mit dem Albumin bzw.…”

Section: Resümeeunclassified

Nierenfunktionsparameter bei Neugeborenen und Säuglingen

Kallerhoff¹

2008

Aktuel Urol

View full text Add to dashboard Cite

Section: Resümeeunclassified

Nierenfunktionsparameter bei Neugeborenen und Säuglingen

Kallerhoff¹

2008

Aktuel Urol

View full text Add to dashboard Cite

“…Biological activity exerted by peptides niay cause toxic phenomena at the same time a s pharmacological effects occur; in this case, toxicity is considered as a specific side-effect of peptides [66,671. Biological activity exerted by peptides niay cause toxic phenomena at the same time a s pharmacological effects occur; in this case, toxicity is considered as a specific side-effect of peptides [66,671.…”

Section: Toxicitymentioning

confidence: 99%

Pharmacological elements in clinical application of synthetic peptides

Lauta

2000

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

The research carried out on the biological properties of synthetic peptides and the possibility of obtaining them in adequate amounts through the recombinant DNA technology allows their use as therapeutical agents. Procedures following the synthesis of peptides must be performed in order to verify their structure, conformation, immunogenicity and biological activity and to make them suitable for clinical applications. The size of synthetic peptides together with some modifications such as amidation, acetylation and sulfatation must be taken into consideration as they may have a significant impact on half-life, stability and biological activity. Endothelial, epithelial and enzymatic interference which may hinder the absorption of drugs must be evaluated in order to choose the most appropriate route of administration. The considerable bioavailability related to the intravenous route, the effectiveness of the circulation of the intramuscular route and the possibility of reaching specific targets by the intra-arterial route must also be taken into consideration. There is the possibility of applying transdermal therapeutic systems and transdermal iontophoresis only for peptides of low molecular weight. Among synthetic peptides provided with antianaemic activity, erythropoietin, growth factors and interleukin 3 must be mentioned because of their effectiveness both in optimal stimulation of melopoiesis after chemotherapy or bone-marrow transplantation and in the treatment of anaemia occurring during chronic renal failure. Furthermore, interferon alpha was shown to be one of the most used synthetic peptides provided with antiviral and antineoplastic activity. Remarkable results have been obtained in the treatment of chronic hepatitis C, haematological malignancies and some solid tumours. More recently, interleukin 2 has been tested in the treatment of melanoma and renal cancer, inducing a reasonable proportion of overall response rate. Finally, the antagonist of gonadotropin-releasing-hormone may be regarded as effective agent both in the treatment of prostate cancer and in the inhibition of luteinizing-hormone surges during controlled ovarian stimulation. Toxic side effects can be related to the administered dose as well as to metabolites derived from bacteria in which peptides have been synthesized.

show abstract

“…In the early 1980s, we observed that mAbs were not tumor-specific [1]. We tested the specificity of 15 of the best-documented mAbs against bladder tumor antigen from seven world centers and found that none of them was tumor-or organ-specific [4]. It has not yet been possible to develop human tumor-specific antibodies that re act exclusively with carcinoma tissue of an organ and not with the healthy tissue.…”

Section: Quantitative Analysismentioning

confidence: 99%

“…Fluorescence-coupled visualization techniques, although simple and thus commonly used to demonstrate antibody binding, are not suitable for quantitative assessment because they do not permit struc tural evaluation of labeled urothelial cells. We examined and compared most of the interesting mAbs to tumor-associated antigen of bladder tumors that were reported up to 1986 [4]. We applied and quantitatively analyzed the antibodies in urine from 20 patients with bladder tumors, 14 with benign prostatic adenoma, and 13 with nephrolithiasis.…”

Section: Quantitative Analysismentioning

confidence: 99%

The Significance of Immune Cytological Diagnostics for Bladder Carcinoma

Huland¹,

Huland²,

Meier³

et al. 1991

Oncol Res Treat

View full text Add to dashboard Cite

We have shown that 15 different monoclonal antibodies (mAb) directed against transitional cell carcinoma (TCC) stain to a certain degree normal urothelium and normal other cells, like granulocytes and kidney cells. However, quantitative differences in antigen expression between normal and tumor cells and the exclusion of non-urothelial cells (like granulocytes) from a quantitative evaluation are the key to the successful diagnostic use of mAb in TCC. This provides the basis for quantitative immunocytology (Quic) in urine sediments. Quic with our mAb 486 p 3/12 is the most sensitive TCC marker with equal sensitivity of up to 90% in grade I, II, and III. The value of Quic in the follow-up of patients with superficial bladder carcinomas was demonstrated in a prospective study. As with other tumor markers, screening with Quic cannot be recommended because of insufficient specificity, especially in stone patients.

show abstract

Immunotherapy

Cited by 3 publications

References 96 publications

Nierenfunktionsparameter bei Neugeborenen und Säuglingen

Nierenfunktionsparameter bei Neugeborenen und Säuglingen

Pharmacological elements in clinical application of synthetic peptides

The Significance of Immune Cytological Diagnostics for Bladder Carcinoma

Contact Info

Product

Resources

About